The persistence of humoral and cellular immunities more than three decades after smallpox vaccination

Clinical Microbiology and Infection

Volumn 13, Issue 1, 2007, Pages 91-93

  Kim, S H ^a   Yeo, S G ^a   Park, K H ^a   Bang, J W ^a   Kim, H B ^a   Kim, N J ^a   Jee, Y ^a   Cho, H ^a   Oh, M D ^a   Choe, K W ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Immunity; Persistence; Smallpox; Vaccination; Vacciniavirus

Indexed keywords

NEUTRALIZING ANTIBODY; SMALLPOX VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION RESISTANCE; KOREA; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MEMORY T LYMPHOCYTE; PERSISTENT INFECTION; PRIORITY JOURNAL; SMALLPOX; VACCINIA VIRUS;

VACCINIA VIRUS; VARIOLA VIRUS;

EID: 33845284895     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01576.x     Document Type: Article

References (19)

1. Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131-1137.
2. Kim SH, Yeo SG, Jang HC et al. Clinical responses to smallpox vaccine in vaccinia-naïve and previously vaccinated populations: Undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial. J Infect Dis 2005; 192: 1066-1070.
3. Kim SH, Bang JW, Park KW et al. Evaluation of residual immunity to smallpox by means of an intradermal skin test with inactivated vaccinia virus. J Infect Dis 2006; 194: 377-384.
4. El-Ad B, Roth Y, Winder A et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990; 161: 446-448.
5. Hatakeyama S, Moriya K, Sijo M et al. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin Diagn Lab Immunol 2005; 12: 520-524.
6. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171: 4969-4973.
7. Combadiere B, Boissonnas A, Carcelain G et al. Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. J Exp Med 2004; 199: 1585-1593.
8. Hsieh SM, Pan SC, Chen SY, Huang PF, Chang SC. Age distribution for T cell reactivity to vaccinia virus in a healthy population. Clin Infect Dis 2004; 38: 86-89.
9. Worthington M. Role of antibody in recovery from severe vaccinia virus infection. Clin Infect Dis 2003; 37: 864-865.
10. Mack TM, Noble JJ, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972; 21: 214-218.
11. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull WHO 1975; 52: 307-311.
12. Hobday TL. Antivaccinial gammaglobulin in the control of smallpox. Lancet 1962; i: 907-908.
13. Kempe CH. The use of hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull WHO 1961; 25: 41-48.
14. Law M, Putz MM, Smith GL. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 2005; 86: 991-1000.
15. Viner KM, Isaacs SN. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccines. Microb Infect 2005; 7: 579-583.
16. Davies DH, McCausland MM, Valdez C et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005; 79: 11724-11733.
17. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972; 125: 161-169.
18. Heiner GG, Fatima N, Daniel RW, Cole JL, Anthony RL, McCrumb FR. A study of inapparent infection in smallpox. Am J Epidemiol 1971; 94: 252-268.
19. Henderson DA, Borio LL, Lane JM. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA, eds, Vaccine, 4th edn. Philadelphia: Elsevier, 2004; 123-153.